Galderma stock slips as CFO transition and December vote draw focus
Published on 11/12/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey governance milestones ahead
- Galderma's CFO transition remains linked to a planned succession process.
- Shareholders are scheduled to vote on board changes at the December 3 extraordinary meeting.
- The April AGM approved a gross dividend and the company's 2025 reporting package.
Galderma stock traded at 210.25 euros on Lang & Schwarz at 17:39 CET on Thursday, November 12, 2026. That was 1.29 percent below the 213.00-euro quote cited in the latest AD HOC NEWS report at 12:16 CET the same day, a comparison with that report rather than a Xetra session move.
Governance transition remains active
Galderma announced on November 2 that Chief Financial Officer Luigi La Corte will leave the dermatology group for a new opportunity. He is expected to remain in the role during a transition period, with further details on the succession process and timetable to follow.
The board has proposed Rosalind Brewer and Petra Rumpf as new directors. The proposals would raise the board's maximum size from 10 to 11 members, while Brewer is also proposed for individual election to the Compensation Committee. Sherilyn McCoy is set to leave the board after seven years because of conflicting obligations.
December vote sets next milestone
The virtual Extraordinary General Meeting is scheduled for Thursday, December 3, 2026, at 14:00 CET. Shareholders are expected to vote on the director appointments and the proposed board-size increase. The meeting gives investors a defined governance event while the CFO succession remains unresolved.
April AGM provides background
At the Annual General Meeting on April 22, shareholders approved all proposals put forward by the board, according to Galderma. The resolutions included a gross dividend of 0.35 Swiss francs per dividend-bearing share, board elections and approval of the 2025 annual financial statements, non-financial report and compensation report.
Galderma Group AG
- ISIN: CH1335392721
- Ticker: GALD
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz quote: 210.25 euros at 17:39 CET on November 12, 2026
- Change since latest AD HOC NEWS report: 1.29 percent lower than 213.00 euros at 12:16 CET on November 12, 2026
- Approved gross dividend: 0.35 Swiss francs per dividend-bearing share
The Swiss market backdrop can be followed in current SMI market coverage.
